Guerrero-Martínez FJ

Idioma: Inglés [English version]
Referencias bibliográficas: 35
Paginas: s182-191
Archivo PDF: 353.69 Kb.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Herna?ndez-Alcaraz C, Aguilar-Salinas CA, Mendoza-Herrera K, Pedroza-Tobi?as A, Villalpando S, Shamah-Levy T et al. Dyslipidemia prevalence, awareness, treatment and control in Mexico: results of the Ensanut 2012. Salud Pública Mex. 2020; 622: 137-146.

2. Aguilar-Salinas CA, Gómez-Díaz RA, Gómez-Pérez FJ. Dislipidemias; de lo clínico a lo molecular. Capítulo I, definición de dislipidemia. México, Editorial Intersistemas. 2008, 1-51.

3. Goldstein JL, Brown MA. Century of cholesterol and coronaries: From Plaques to Genes to Statins. Cell. 2015; 161: 61-172.

4. Glass CK, Witztum JL. Atherosclerosis: the road ahead. Cell. 2001; 104: 503-516.

5. Libby O. Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med. 2013; 368: 2004-2013.

6. Libby P, Pasterkamp G, Crea F, Jang IK. Reassessing the mechanisms of acute coronary syndromes. The "vulnerable plaque" and superficial erosion. Circ Res. 2019; 124: 150-160.

7. Vergallo R, Crea F. Atherosclerotic plaque healing. N Engl J Med. 2020; 383: 846-857.

8. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017; 38: 2459-2472.

9. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L et al. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019; 41: 111-188.

10. Langlois MR, Chapman MJ, Cobbaert CH, Mora S, Remaley AT, Ros E et al. Quantifying atherogenic lipoproteins: current and future challenges in the era of personalized medicine and very low concentrations of LDL cholesterol. a consensus statement from EAS and EFLM. Clin Chem. 2018; 64(7): 1006-1033.

11. Van der Valk FM, Bekkering S, Kroon J, Yeang C, Van den Bossche J, van Buul JD et al. Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans. Circulation. 2016; 134: 611-624.

12. Gencer B, Kronenberg F, Stroes ES, Mach F. Lipoprotein(a): the revenant. Eur Heart J. 2017; 38: 1553-1560.

13. Watts GF, Chan DC, Somaratne R, Wasserman SM, Scott R, Marcovina SM, Barrett PHR. Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics. Eur Heart J. 2018; 39: 2577-2585.

14. Pirillo A, Catapano AL. PCSK9 inhibition and Lp(a) reduction: another piece of the puzzle? Eur Heart J. 2018; 39: 2586-2588.

15. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ et al. 2019 ACC/AHA Guideline on the primary prevention of cardiovascular disease. A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019; 140: e596-646.

16. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Cholesterol Treatment Trialists Collaboration. Lancet. 2010; 376: 1670-1681.

17. Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Cholesterol Treatment Trialists' (CTT) Collaboration. Lancet. 2012; 380: 581-590.

18. Michos ED, McEvoy JW, Blumenthal RS. Lipid management for the prevention of atherosclerotic cardiovascular disease. N Engl J Med. 2019; 381: 1557-1567.

19. Nissen SE, Tuzcu EM, Schoenhagen P, Brown G, Ganz P, Vogel RA et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004; 291: 1071-1080.

20. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM et al. ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: The ASTEROID trial. JAMA. 2006; 295: 1556-1565.

21. Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011; 365: 2078-2087.

22. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P et al. for the IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015; 372: 2387-2397.

23. Tsujita K, Sugiyama S, Sumida H, Shimomura H, Yamashita T, Yamanaga K et al, for the PRECISE-IVUS Investigators. Impact of Dual Lipid-Lowering Strategy with Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients with Percutaneous Coronary Intervention. The Multicenter Randomized Controlled PRECISE-IVUS Trial. J Am Coll Cardiol. 2015; 66: 495-507.

24. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017; 376: 1713-1722.

25. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018; 379: 2097-2107.

26. Bhatt DL, Steg PGP, Miller M, Brinton EA, Jacobson TA, Ketchum SB et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019; 380: 11-22.

27. McCormack T, Dent R, Blagden M. Very low LDL-C levels may safely provide additional clinical cardiovascular benefit: the evidence to date. Int J Clin Pract. 2016; 70: 886-897.

28. Goodman DS, Hulley SB, Clark LT, Davis CE, Fuster V, LaRosa JC et al. Report of the national cholesterol education program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Arch Intern Med. 1988; 148: 36-69.

29. National Cholesterol Education Program. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II). Circulation. 1994; 89: 1333-1445.

30. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001; 285: 2486-2497.

31. Grundy SM, Cleeman JI, Merz CNB, Brewer HB, Clark LT, Hunninghake DB et al. Implications of recent clinical trials for the national cholesterol education program adult treatment panel iii guidelines. Circulation. 2004; 110: 227-239.

32. Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O et al. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011; 32: 1769-1818.

33. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H et al. 2016 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart. 2016; 37 (39): 2999-3058.

34. Stone NJ, Robinson JG, Lichtenstein AH, Merz NB, Blum CB, Eckel RH et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014; 129 (Suppl 2): S1-S45.

35. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/ PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019; 139 (25): e1046-e1081.